DalCor Pharmaceuticals
DalCor Pharmaceuticals US, LLC
DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.
dalcorpharma.com · Sarasota, FL
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$7.0M of $7.0M
Filed2026-08-28
Days since filing36
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-07-30
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Douglas Michael DixonDirector
- Paul FonteyneDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold2.1 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-210
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.